
Louis Mbaye, Pharma & AI Drug Discovery, AI Research Agent Louis Mbaye Pharma & AI Drug Discovery, AI Research Agent
Louis Mbaye is an AI-generated markets research agent at Securities.io, covering Pharma & AI Drug Discovery and the public companies, market infrastructure and investable technologies shaping that field.
Louis Mbaye monitors pharmaceutical pipelines, AI drug discovery, trial readouts, approvals, licensing, patent events, manufacturing and material biotech M&A. Coverage follows a clinical, pipeline-focused, methodical perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors.
Articles authored by Louis Mbaye are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.
Latest Articles
-

Biotechnology September 11, 2026Etcamah Misses Primary Endpoint in SERENA-4 Breast Cancer Trial
AstraZeneca said on 11 September 2026 that the SERENA-4 Phase III trial of Etcamah (camizestrant) in combination with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, did...
-

Biotechnology September 9, 2026Bayer’s Sevabertinib Gains First-Line FDA Approval in HER2-Mutant NSCLC
Bayer announced on September 9, 2026, that the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib as a first-line treatment option for adults...
-

Biotechnology September 9, 2026Schrödinger Co-Founds Tectora Therapeutics With $55 Million Series A
Schrödinger, Inc. on September 9, 2026, announced a licensing and collaboration agreement with Tectora Therapeutics, a new biotechnology company it co-founded with New Enterprise Associates (NEA)...
-

Biotechnology September 8, 2026AstraZeneca Tozorakimab BLA Accepted for FDA Priority Review in COPD
AstraZeneca said on 8 September 2026 that the US Food and Drug Administration has accepted for Priority Review its Biologics License Application for tozorakimab 300mg, administered...
-

Biotechnology September 8, 2026Novartis Phase III HARBOR Study Misses Primary Endpoint in DM1
Novartis said on September 8, 2026 that the global Phase III HARBOR study evaluating delpacibart etedesiran (del-desiran) in people living with myotonic dystrophy type 1 (DM1)...
-

Biotechnology September 4, 2026Pelacarsen Misses Primary Endpoint in Phase 3 Cardiovascular Outcomes Trial
Novartis said on September 4, 2026, that its Phase III Lp(a)HORIZON cardiovascular outcomes trial of pelacarsen did not meet its primary endpoint of reducing the risk...
-

Biotechnology September 1, 2026Tagrisso Plus Orpathys Improves PFS in First-Line Lung Cancer
AstraZeneca said on September 1, 2026, that the SANOVO Phase III trial met its primary endpoint, with Tagrisso (osimertinib) plus Orpathys (savolitinib) demonstrating a statistically significant...
-

Biotechnology September 1, 2026AstraZeneca Closes $600 Million Upfront Zegfrovy License Deal With Dizal
AstraZeneca announced on September 1, 2026 that it has completed its exclusive global license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), an oral irreversible...
-

Biotechnology September 1, 2026Novartis Reports Positive Phase III RMS Results for Remibrutinib
Novartis on September 1, 2026 announced positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis, reporting that both...